Media headlines about Aerie Pharmaceuticals (NASDAQ:AERI) have trended somewhat positive on Tuesday, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aerie Pharmaceuticals earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.9319537461577 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:

Aerie Pharmaceuticals (AERI) opened at $61.40 on Tuesday. The company has a current ratio of 15.24, a quick ratio of 15.24 and a debt-to-equity ratio of 0.78. Aerie Pharmaceuticals has a one year low of $35.50 and a one year high of $66.60.

A number of research firms have recently commented on AERI. Canaccord Genuity set a $65.00 target price on Aerie Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, August 8th. Zacks Investment Research cut Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, August 28th. Mizuho began coverage on Aerie Pharmaceuticals in a research note on Wednesday, September 6th. They issued a “buy” rating and a $70.00 target price for the company. Needham & Company LLC restated a “buy” rating and issued a $65.00 target price on shares of Aerie Pharmaceuticals in a research note on Sunday, September 17th. Finally, Cowen restated a “buy” rating on shares of Aerie Pharmaceuticals in a research note on Thursday, October 5th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $71.43.

COPYRIGHT VIOLATION WARNING: This piece was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/05/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-aerie-pharmaceuticals-aeri-stock-price.html.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Insider Buying and Selling by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Stock Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.